Nicholas A. Butowski, MD

---

Additional Websites

• Physician Referral Directory

---

Education

Northwestern University, Evanston, IL, BA, 1991-1995, Philosophy/Religion
University of Illinois at Chicago, Chicago, IL, MD, 1995-1999
Evanston-Northwestern Hospital, Evanston, IL, Intern, 1999-2000, Medicine
University of California, San Francisco, San Francisco, CA, Fellow, 2003-2005, Neuro-Oncology

---

Professional Experience

• 2000-2003
  Residency in Neurology; Department of Neurology, University of California, San Francisco, CA
• 2003-2004
  Fellow, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
• 2004-2005
  Clinical Instructor, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
• 2005-present
  Assistant Clinical Professor, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
• 2006-present
  Director of Clinical Services, Dept. of Neurological Surgery, Neuro-Oncology Service, Brain Tumor Research Center, University of California, San Francisco (UCSF)
• 2005-present
  Assoc Member of the Brain Tumor Research Center, Dept. of Neurological Surgery, UCSF
• 2005-present
  Assoc Member of the Comprehensive Cancer Center, UCSF
• 2009-present
  Co-chair, CNS Cancer Program Site Committee
• 2009-present
  Member, UCSF Cancer Program Protocol Review Committee
• 2009-present
  Member, National Comprehensive Cancer Center Network CNS Cancer Guideline Committee

---

Selected Publications

1. Lupo JM, Essock-Burns E, Molinaro AM, Cha S, Chang SM, Butowski N, Nelson SJ. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro Oncol. 2013 Apr; 15(4):480-9.
   View on PubMed
2. Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2013 Feb; 15(2):189-97.
   View on PubMed
3. Butowski N, Chang SM. Endpoints for clinical trials and revised assessment in neuro-oncology. Curr Opin Neurol. 2012 Dec; 25(6):780-5.
   View on PubMed
4. Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT. Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein. Clin Cancer Res. 2013 Jan 1; 19(1):205-14.
   View on PubMed
5. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012 Jul 1; 30(19):2307-13.
   View on PubMed
6. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70.
   View on PubMed
7. Butowski NA, Chang SM. General and neurological complications of targeted therapy. Handb Clin Neurol. 2012; 105:937-45.
   View on PubMed
8. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 1; 29(31):4175-80.
   View on PubMed
9. Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8.
   View on PubMed
10. Butowski N. Anti-angiogenic therapy in glioma. Clin Transl Oncol. 2011 May; 13(5):294-300.
    View on PubMed
11. Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central nervous system cancers. J Natl Compr Canc Netw. 2011 Apr; 9(4):352-400.
    View on PubMed
12. Parvataneni R, Polley MY, Freeman T, Lamborn K, Prados M, Butowski N, Liu R, Clarke J, Page M, Rabbitt J, Fedoroff A, Clow E, Hsieh E, Kivett V, Deboer R, Chang S. Identifying the needs of brain tumor patients and their caregivers. J Neurooncol. 2011 Sep; 104(3):737-44.
    View on PubMed
13. Butowski N. Medical management of brain metastases. Neurosurg Clin N Am. 2011 Jan; 22(1):27-36, v-vi.
    View on PubMed
14. Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, McDermott MW, Parsa AT, Berger MS, Aghi MK. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011 Jun; 114(6):1609-16.
    View on PubMed
15. Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski NA, Chang SM, Nelson SJ. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011 Jan; 13(1):119-31.
    View on PubMed
16. Khayal IS, Polley MY, Jalbert L, Elkhaled A, Chang SM, Cha S, Butowski NA, Nelson SJ. Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Neuro Oncol. 2010 Sep; 12(9):908-16.
    View on PubMed
17. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010 Aug; 12(8):855-61.
    View on PubMed
18. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010 Mar; 67(3):279-83.
    View on PubMed
19. Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010 Jun; 12(6):608-13.
    View on PubMed
20. Butowski N. Immunostimulants for malignant gliomas. Neurosurg Clin N Am. 2010 Jan; 21(1):53-65.
    View on PubMed

View on UCSF Profiles